Vivli’s Post

We are thrilled to share that C-Path has entered into a strategic data-sharing partnership with Vivli, an independent nonprofit dedicated to advancing global clinical trials data sharing. This collaboration marks a significant step forward in breaking silos and making rare disease data more accessible to researchers and stakeholders worldwide. The partnership will see data sets from Biogen, including the phase II PASSPORT trial in progressive supranuclear palsy and two choroideremia datasets, available on both C-Path's Rare Disease Cures Accelerator Data and Analytics Platform and Vivli's Clinical Trials Data Platform. This alignment reinforces our shared commitment to the FAIR principles of data sharing, ensuring that valuable research data is findable, accessible, interoperable, and reusable. “We are thrilled to announce that Vivli, RDCA-DAP®, and Biogen collaborated to integrate a Progressive Supranuclear Palsy clinical trial dataset into both partnering platforms, as well as two datasets in choroideremia, our first data in rare eye disorders,” shared Alexandre Bétourné, PhD, PharmD, PMP, Executive Director for RDCA-DAP at C-Path. Together, we're accelerating the development of treatments for rare diseases by fostering collaboration and data sharing among academic researchers, industry leaders, healthcare organizations, and patient advocacy groups. Julie Wood Janet Krause #CPath #Vivli #DataSharing #RareDiseases #Collaboration #ClinicalTrials #RDCADAP #DrugDevelopment